Fresenius Medical Care AG: management transactions · Germany · BaFin

About Fresenius Medical Care AG

Fresenius Medical Care AG is a global healthcare leader focused on renal disease treatment. Listed on Xetra/Frankfurt (DAX/MDAX/SDAX) in Germany (Germany), the company has built its franchise around an integrated model combining dialysis services, treatment technologies, and medical consumables. Its headquarters are in Bad Homburg vor der Höhe, Germany, and the group describes itself as the world’s leading provider of products and services for people with kidney disease. The company states that more than 4.5 million people worldwide regularly undergo dialysis, highlighting the scale of the addressable market. The group’s roots are tied to Fresenius, with an early development path in dialysis therapies followed by international expansion through clinic networks and manufacturing operations. Today, Fresenius Medical Care spans the full dialysis value chain: in-center care, selected home-based therapies in certain markets, and the production of equipment and disposables. Its core business lines include Care Delivery, which covers dialysis clinic operations and patient care services; and Care Enablement, which houses products and technologies such as hemodialysis machines, dialyzers, and related consumables. The company also provides products and solutions used in acute care, peritoneal dialysis, and advanced treatment settings. From a competitive perspective, Fresenius Medical Care holds a leading position thanks to its vertical integration, global footprint, and industrial scale. The company operates roughly 3,600 dialysis centers worldwide and around 35 production sites across multiple continents. This structure supports commercial resilience, but the business is also exposed to reimbursement pressure, labor costs, currency effects, and patient-volume trends, especially in the United States where the dialysis market is more fragmented. Recent highlights include the launch of the FME Reignite strategy in 2025, aimed at improving profitability and long-term value creation. Full-year 2025 performance showed improved organic revenue growth, higher operating income, and stronger cash flow, while net debt continued to decline. Management also announced a new capital allocation framework including share repurchases. More recently, Fresenius Medical Care has continued rolling out its 5008X CAREsystems in the U.S. and completed the acquisition of key manufacturing sites in Germany, reinforcing its industrial base and its emphasis on operational execution.